293 results
Page 7 of 15
8-K
EX-99.1
wulj775jw
9 Jul 19
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
11:20am
8-K
EX-99.1
j69o15jndftbts
31 May 19
Other Events
9:09am
8-K
EX-99.1
e0km6o0m5wu40nldz1zr
23 May 19
Other Events
9:25am
POS AM
cqk8mtd08e rqr
21 May 19
Prospectus update (post-effective amendment)
9:11am
8-K
EX-99.1
6md1 s11rmc7a
13 May 19
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price
3:47pm
8-K
EX-10.1
wy1cklai4ky4e
13 May 19
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price
3:47pm
POS AM
nbkcuj1
10 May 19
Prospectus update (post-effective amendment)
4:57pm
8-K
EX-99.1
d3t87zxr 8k
8 May 19
Trovagene Announces First Quarter 2019 Results and Highlights
12:00am
POS AM
3n7jepp9
25 Apr 19
Prospectus update (post-effective amendment)
12:00am
8-K
EX-99.1
t594ed2t7r5s
23 Apr 19
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
2:39pm
8-K
EX-10.1
h7r2l4xwd3pdnkulem1
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am
8-K
EX-99.1
q11zrekwq 5rzm7hw5
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am
8-K
EX-99.2
1jcejni9twyjjto
5 Apr 19
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
10:03am
8-K
EX-99.1
jfx lw9fliqxsk
2 Apr 19
PSA trajectory in patient achieving primary efficacy endpoint indicates alteration of the natural history of early abiraterone (Zytiga®) resistance
10:48am
8-K
EX-99.1
qeqw8 prv
1 Apr 19
Other Events
1:10pm
8-K
EX-99.1
rsuxngwd
6 Mar 19
Trovagene Announces Fourth Quarter and Full-Year 2018 Results
9:43pm